Recalls, new research, and safety signals on the exact supplements and medications you take — in one weekly brief. Quiet until something matters.
CAERS reports linked to intake above 4,000 IU/day. Discuss with your doctor. Source ↗
New meta-analysis published. Summary inside — research, not advice.
Research coverage updates as new studies are published — a signal for your own reading, not a verdict.
See a full sample →Built on public data from U.S. FDA · NIH · PubMed · peer-reviewed research
We watch the world for what changes about them.
If a recall or contamination notice hits a product or ingredient you track, you hear about it — with the official source linked.
When new studies on your ingredients are published, we summarize what changed — with an evidence score that updates as findings land.
Real-world safety reports from FDA's CAERS database — filtered to your ingredients and linked to the original source.
Enter the supplements and medications you take — product and brand. Once.
Public sources, continuously — recall feeds, published research, price data.
Only what actually touches your stack gets through. No noise, no spam.
One calm email a week, with sources you can check yourself.
A quiet week still gets a brief — “nothing changed, we checked.”
Cancel anytime.
No. Vialsense is informational monitoring of public sources. It doesn’t diagnose, and it isn’t a substitute for your doctor or pharmacist — always consult a professional before changing anything.
No. We’re independent. We don’t sell products or take affiliate kickbacks — the subscription is our only revenue.
Public sources — including the FDA, the NIH, and published research. Every item in your brief links back to its original source so you can verify it.
It reflects the weight of published research behind the ingredients in your stack, and shifts as new studies are published. It’s a signal for your own reading — not a verdict or medical recommendation.
Yes. We collect the minimum needed to run your brief, never sell your data, and you can delete everything anytime.
We’re starting US-focused, with more regions on the roadmap.